Quantitative HDL Proteomics Identifies Peroxiredoxin-6 as a Biomarker of Human Abdominal Aortic Aneurysm by Burillo, Elena et al.
1Scientific RepoRts | 6:38477 | DOI: 10.1038/srep38477
www.nature.com/scientificreports
Quantitative HDL Proteomics 
Identifies Peroxiredoxin-6 as a 
Biomarker of Human Abdominal 
Aortic Aneurysm
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High-density lipoproteins (HDLs) are complex protein and lipid assemblies whose composition is known 
to change in diverse pathological situations. Analysis of the HDL proteome can thus provide insight 
into the main mechanisms underlying abdominal aortic aneurysm (AAA) and potentially detect novel 
systemic biomarkers. We performed a multiplexed quantitative proteomics analysis of HDLs isolated 
from plasma of AAA patients (N = 14) and control study participants (N = 7). Validation was performed 
by western-blot (HDL), immunohistochemistry (tissue), and ELISA (plasma). HDL from AAA patients 
showed elevated expression of peroxiredoxin-6 (PRDX6), HLA class I histocompatibility antigen  
(HLA-I), retinol-binding protein 4, and paraoxonase/arylesterase 1 (PON1), whereas α-2 macroglobulin 
and C4b-binding protein were decreased. The main pathways associated with HDL alterations in AAA 
were oxidative stress and immune-inflammatory responses. In AAA tissue, PRDX6 colocalized with 
neutrophils, vascular smooth muscle cells, and lipid oxidation. Moreover, plasma PRDX6 was higher 
in AAA (N = 47) than in controls (N = 27), reflecting increased systemic oxidative stress. Finally, a 
positive correlation was recorded between PRDX6 and AAA diameter. The analysis of the HDL proteome 
demonstrates that redox imbalance is a major mechanism in AAA, identifying the antioxidant PRDX6 as 
a novel systemic biomarker of AAA.
Abdominal aortic aneurysm (AAA) is a major health problem, with a prevalence of ~2% in adults aged over 
65 years1,2 and causing about 1–2% of male deaths in economically developed societies3. Clinically, AAA is 
defined as a permanent dilation of the aortic diameter by more than 3 cm or more than 50% of the initial value. 
Mechanistically, AAA is characterized by the formation of an intraluminal thrombus (ILT), proteolysis, oxida-
tive stress, immune inflammatory response, angiogenesis and fibrosis. Currently, the only way to prevent aortic 
rupture in patients with an AAA > 5.5 cm is surgery. AAA is usually asymptomatic and is often detected as an 
incidental finding during the investigation of an unrelated problem or as a consequence of radiological screening. 
Moreover, diameter growth is discontinuous, with periods of growth alternating with periods of stability, making 
prognosis difficult4. There is thus a pressing need to identify novel biomarkers of the presence and evolution of 
AAA, which provide insight into the pathological mechanisms of the disease.
The most convenient source of a systemic AAA biomarker is blood plasma. Our group and others have pre-
viously analyzed AAA patient plasma using a variety of proteomics approaches5–9. However, the high dynamic 
range of protein concentrations in plasma makes it difficult to quantify proteins present in low amounts, even 
after depletion of the most abundant proteins. To circumvent this problem, some authors have concentrated on 
the analysis of specific plasma subproteomes, such as high-density lipoproteins (HDLs).
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HDLs are a transport platform of lipids and proteins. HDLs are responsible for transporting excess cholesterol 
from peripheral tissues to the liver for its elimination in feces and bile. Clinical and epidemiological studies con-
sistently link low HDL cholesterol levels to an elevated risk of cardiovascular disease. A recent meta-analysis also 
revealed a negative association of HDL cholesterol levels with AAA in most studies10. HDLs are additionally a trans-
port platform for constitutive and non-permanently associated plasma proteins. Screening of the HDL proteome 
has identified dramatic protein alterations in a variety of disease contexts, including cardiovascular diseases11–15. 
HDLs have several important cardiovascular protective properties, including anti-oxidant, anti-inflammatory, 
and antithrombotic effects16,17. These properties are attributable to HDL-associated proteins, and it is increas-
ingly accepted that HDL composition, rather than quantity, is more important for its vasculo-protective 
activities. We previously demonstrated impaired anti-proteolytic18 and anti-oxidative functions19  
in HDLs from human AAA. This effect has been linked to altered HDL protein composition or to impaired func-
tion of individual components. However, the protein alterations taking place in the HDL proteome in AAA have 
not been reported to date.
Here, we performed a multiplexed quantitative proteomics study of HDL-protein alterations in AAA. Systems 
biology analysis revealed an association of AAA with an increased HDL content of proteins related to redox 
homeostasis, most clearly evident in the increased levels of peroxiredoxin-6 (PRDX6). Circulating levels of 
PRDX6 are also increased in AAA-patient plasma, and PRDX6 levels correlate positively with AAA size, identi-
fying PRDX6 as a promising biomarker of AAA.
Results
Analysis of the human HDL proteome in AAA. HDL particles were isolated from plasma and subjected 
to trypsin digestion. The resulting peptides were iTRAQ-labeled and combined in 7 independent experiments for 
LC-MS/MS analysis (Fig. 1). The protein composition of the HDL samples was characterized by spectral count-
ing of the 7 HDL pools. At a 1% FDR threshold, 112 proteins were identified as HDL particle constituents in at 
least 3 experiments (Supplementary Table S1). As expected, ApoA1 was one of the most abundant HDL proteins, 
representing 33% of total protein composition. Other abundant HDL proteins were α-1-antitrypsin, comple-
ment C3, apolipoproteins D, E and M, and paraoxonase/arylesterase 1 (3–4% each) (Supplementary Figure S1). 
Albumin and ApoB100 were also identified but were not included in the analysis because they are abundant 
Figure 1. Multiplexed analysis of individual HDL proteomes from AAA patients: shotgun proteomics 
workflow. (a) HDL particles were isolated by sequential ultracentrifugation. Protein extracts were loaded onto 
SDS-PAGE gels, and proteins were concentrated in the stacking gel. After in-gel trypsin digestion, peptides were 
labeled with 4-plex iTRAQ reagents and then analyzed by LC-MS/MS. (b) A total of 7 iTRAQ experiments were 
performed. In each experiment, samples from 2 AAA patients and 1 control subject were compared with an 
internal control. The internal control was a pool of all the individual samples used in the study. (c) The statistical 
model for the quantitative data decomposes the total technical variance into the spectral, peptide, and protein 
variance components and provides a general framework to fully integrate quantitative and error information, 
allowing a comparative analysis of the results obtained from the 7 iTRAQ experiments.
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plasma proteins and are considered concomitant contaminants of HDLs obtained by ultracentrifugation12. Of the 
proteins identified in this study, 78 have previously been described as HDL-associated (Supplementary Table S1). 
These proteins comprise 92% of the absolute HDL protein content. A further 34 HDL proteins identified here, 
representing 8% of total HDL composition, have not been previously linked to HDL (Supplementary Table S1).
The complete list of quantitative results at the protein level is presented in Supplementary Table S2. Within 
the set of proteins found in at least 3 iTRAQ experiments, α-2 macroglobulin and C4b-binding protein were the 
two proteins showing the most prominent abundance deficit in HDL from AAA patients compared with controls, 
whereas PRDX6, HLA-I, retinol-binding protein 4, and PON1 were the proteins showing the largest abundance 
increases (Fig. 2).
Among the identified proteins, PRDX6 attracted our interest because it showed the most significant difference 
between AAA patients and controls and had not previously been linked to HDL or AAA. The quantitative pro-
teomics results for PRDX6 were therefore validated by western blot in the same 14 AAA and 7 control samples 
(Fig. 3a and Supplementary Figure S2). Western blot was also used to validate HLA-I and PON1, which were also 
not previously linked to AAA (Fig. 3b and Supplementary Figure S2).
To explore whether the observed protein changes were discrete events or part of a more general pattern of 
HDL protein alterations, we performed a systems biology analysis using the SBT model, a statistical framework 
that captures functional alterations produced by coordinated protein abundance changes20. SBT analysis was 
performed on the averaged protein quantifications obtained from the integration of the experiments. We detected 
significant increases in proteins related to redox homeostasis (p = 0.00001, FDR = 0.00045), MHC class I complex 
(p = 0.00178, FDR = 0.01386), acute phase response (p = 0.03597, FDR = 0.06570), and platelets (p = 0.00002, 
FDR = 0.00076), whereas complement activation proteins from the classical pathway were decreased (p = 0.00042, 
FDR = 0.00787) (Fig. 2). With the exception of α-2 macroglobulin, all the proteins detected individually as being 
significantly altered were found among these altered functional categories, suggesting that they were the most 
evident consequence of a general reconfiguration of the HDL proteome. This interpretation was reinforced by 
Figure 2. Protein abundance changes in the HDL proteome of AAA patients. Quantitative data for proteins 
belonging to significantly altered categories according to the colour scale at the bottom. Statistically significant 
changes (p-values < 0.05; FDR < 0.05) are shown in bold.
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network analysis, which indicated that most of the altered HDL proteins were interconnected in a dense interac-
tion network containing most of the quantified HDL proteins (Fig. 3b).
Tissue expression of PRDX6 in AAA. Of the validated proteins, we focused on PRDX6 because it reflects 
the generalized alteration in proteins implicated in redox homeostasis, the functional category most clearly 
changed in the HDL proteome of AAA patients. Immunohistochemical analysis of PRDX6 expression and local-
ization in the ILT obtained from AAA patients revealed intense PRDX6 immunostaining associated with areas 
of neutrophil infiltration and RBC degeneration (Figs 4 and 5). Examination of the aortic wall of AAA patients 
showed strong PRDX6 staining in cholesterol-rich and acellular atherosclerotic plaques in the media layer, but 
also revealed PRDX6 colocalization with vascular smooth muscle cells (VSMCs) (Fig. 4). PRDX6 also colocalized 
in AAA tissue with the lipid peroxidation marker MDA and with ceroids, markers of RBC-associated oxidation 
(Fig. 5).
Circulating PRDX6 in AAA patients. The association of PRDX6 with circulating HDL particles could arise 
from interaction of HDL particles with circulating cells or from direct loading from plasma. The localization of 
PRDX6 in areas of erythrophagocytosis suggested that the presence of PRDX6 in HDL particles could arise, at 
least in part, from the interaction of HDLs with circulating RBCs. To test this hypothesis, we incubated HDLs iso-
lated from healthy subjects with intact or lysed RBCs, and then re-isolated the HDLs to analyse PRDX6 content. 
PRDX6 levels were low in untreated HDLs from healthy subjects, but increased markedly when incubated with 
intact or lysed RBCs (Fig. 6). In control experiments, the abundant RBC protein catalase was taken up by HDL 
particles incubated with lysed RBCs but not by particles incubated with intact RBCs.
Given that HDL is a platform of plasma-associated proteins, we also examined whether PRDX6 is present in 
plasma and could serve as a circulating biomarker of AAA. The plasma concentration of PRDX6 was analyzed in 
a cohort of control individuals (N = 27) and AAA patients (N = 47). Cohort clinical characteristics are shown in 
Table 1. This analysis confirmed the presence of PRDX6 in plasma, which to our knowledge has not been reported 
before, and also revealed higher plasma PRDX6 levels in AAA patients than in controls (21 ± 2 vs 10 ± 2 ng/mL; 
p < 0.01) (Fig. 7a). Multivariate logistic regression analysis of AAA risk factors revealed plasma PRDX6 con-
centration, hypertension, and smoking to be independent predictors of the presence of AAA [Odds Ratio CI 
(95%): 1.060 (1.006–1.117), p < 0.05 for PRDX6; 5.775 (1.670–19.973), p < 0.01 for hypertension; and 10.028 
(1.139–88.311), p < 0.05 for smoking)]. Furthermore, plasma PRDX6 level correlated positively with AAA size 
(r = 0.4, p < 0.001, adjusted for age) (Fig. 7b), reinforcing the potential of PRDX6 as a biomarker of AAA.
Figure 3. Validation and interaction network of the AAA HDL proteome. (a) Representative protein 
validation by western blot. The quantitative results for PRDX6, HLA-I, and PON1 correspond to the same 14 
AAA and 7 control samples used in the proteomic analysis. *p < 0.05, **p < 0.01. (b) Interaction network of 
HDL proteins showing the quantitative data. Significant category changes were clustered.
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Figure 4. PRDX6 immunohistochemistry in AAA tissue. PRDX6 was detected in AAA thrombus 
(colocalizing with neutrophils: PMNs, CD15 staining) and wall (colocalizing with vascular smooth muscle cells: 
VSMC, alpha actin staining). Magnification x10. N = 10.
Figure 5. PRDX6 is expressed in areas of high oxidative stress in AAA tissue. PRDX6 colocalizes with 
ceroids and the lipid peroxidation marker MDA in AAA thrombus and wall. Black arrow indicates typical 
ceroid rings; red arrow indicates degenerated red blood cells. Magnification x10 (x40 in the upper part of 
ceroids and PRDX6). N = 10.
www.nature.com/scientificreports/
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Discussion
HDLs are a complex and heterogeneous family of particles with different lipid and protein cargo and functional-
ity. Different methodologies can be used to isolate HDLs, and not all HDL subpopulations are equivalent. In this 
study, we isolated HDLs by the well-established ultracentrifugation method to isolate most particle subclasses 
and obtain a general proteomics view of HDLs21. However, it is important to note that the small size of HDLs 
means that all the proteins detected and quantified by mass spectrometry are unlikely to reside in the same par-
ticle simultaneously. HDLs are currently regarded as a transport platform of constitutive and non-permanently 
associated lipids and proteins that may have specific functions in disease17. Our analysis identified and quantified 
112 proteins that are consistently associated with HDLs in AAA, of which 34 proteins (8% of HDL by composi-
tion) have not been previously characterized as HDL components. Quantitative proteomics demonstrated that 
HDLs in AAA patients are particularly enriched in PRDX6, HLA-I, retinol-binding protein 4, and PON1 and are 
depleted in C4b-binding protein alpha chain and α-2 macroglobulin, among others. Systems biology analysis 
Figure 6. PRDX6 protein levels in HDL after incubation with RBCs. Western blot of PRDX6 and catalase 
(CAT) in HDL samples incubated with red blood cells (RBC) and lysed RBCs (RBClys). Quantification of 





(N = 14) p-Value
Sex (male/female) 7/0 14/0 ns
Age (years ± SD) 64.9 ± 0.2 66.5 ± 1.2 0.024
Dyslipidemia (%) 64.9 64.9 ns
Current smoker (%) 71.4 50 ns
Diabetes (%) 14.3 14.3 ns
Hypertension (%) 42.9 64.3 ns
Heart Disease (%) 28.6 35.7 ns
Statins (%) 42.9 85.7 0.006
ELISA PRDX6 Control (N = 27)
AAA 
(N = 47) p-Value
Sex (male/female) 27/0 47/0 ns
Age (years ± SD) 64.9 ± 0.2 66.1 ± 5.5 ns
Dyslipidaemia (%) 55.6 56.5 ns
Current smoker (%) 7.4 38.3 0.03
Diabetes (%) 7.4 19.1 ns
Hypertension (%) 25.9 63.8 0.01
Heart Disease (%) 18.5 17 ns
Statins (%) 11.1 38.3 ns
Table 1.  Clinical characteristics of patients and control participants.
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demonstrated that these prominent changes reflect a general increase in proteins related to redox homeostasis, 
acute-phase response, and platelet activation and a decrease in proteins related to complement activation.
The levels and functionality of HDLs are altered in immune inflammatory diseases such as rheumatoid arthri-
tis and systemic lupus erythematosus (SLE)22. Interestingly, serum amyloid A, one of the HDL components we 
found to be increased in AAA, has been suggested to underlie the impaired anti-inflammatory properties of 
HDL in SLE patients23, and lack of endogenous acute-phase serum amyloid A protects against experimental 
AAA24. We also found that AAA patients have below-normal levels of C3, consistent with our previous find-
ing that C3 declines in AAA patient plasma, contrasting its accumulation, consumption, and activation in the 
AAA thrombus25. In addition to the known role of HDLs in the humoral response through modulation of the 
complement system, HDL particles may also influence the innate and adaptive immune responses by mod-
ulating antigen presentation functions in macrophages, B cells, and T cells26. In line with this idea, we found 
that HDLs from AAA patients have increased levels of HLA-I, a central immune system molecule that presents 
endoplasmic-reticulum-derived peptides. The identification of HLA-I in HDL supports the role of HDL as a 
platform for the assembly of innate immune complexes27. Wang et al. demonstrated that dysfunctional HDLs 
promote lipid raft disruption, resulting in less control of antigen presentation and T cell activation28. Together, 
these results support an important role for HDLs in innate and adaptive immune responses, not only as a passive 
transport platform, but also through the active contribution of constituent proteins.
Proteins with roles in redox balance have been previously observed in HDLs12. Here, PON1 and PRDX6, 
two proteins implicated in oxidative stress, were increased in HDL from AAA patients. PON1 is known for its 
HDL-associated antioxidant capacity29. Vaisar et al.12 reported elevated HDL PON1 content in patients with 
coronary artery disease, fitting well with our observation in AAA patients. However, we recently found that 
serum PON1 activity is decreased in AAA patients30, suggesting that PON1 activity is impaired in HDLs of AAA 
patients. PRDX6 belongs to the peroxiredoxin family, a set of enzymes implicated in the protection against oxi-
dation and the control of H2O2 signaling31. Other members of the PRDX family have been previously associated 
with AAA, such as PRDX-1 and PRDX-232,33. However, this is the first time that PRDX6 has been associated 
with both HDL and AAA. PRDX6 is a bifunctional enzyme, with glutathione peroxidase and phospholipase A2 
(PLA2) activities. Because of this dual function, the precise role of PRDX6 is not yet completely understood. 
Similar to other PRDXs, PRDX6 is able to reduce short-chain hydroperoxides through its peroxidase activity. 
However, the PLA2 activity specific to PRDX6 has been linked not only to antioxidant properties34 but also to 
pro-oxidant properties35. Very recently, PRDX6 expression was shown to support higher Nox1-derived superox-
ide production, which was reduced by an inhibitor of PRDX6 phospholipase A2 activity36. The impaired antioxi-
dant function reported in HDLs from AAA patients19 will likely be the result of the imbalance between the levels 
and activities of the various pro- and antioxidant proteins, including PRDX6.
Previous studies of AAA tissue have shown increased levels of various proteins involved in redox balance. 
Elevated levels have been reported of the antioxidant proteins thioredoxin-1, PRDX1, and catalase in AAA throm-
bus, associated with both RBCs and neutrophils37. In the present study, high PRDX6 levels were also observed 
in AAA thrombus, mainly in areas of degenerated RBCs (in the process of erythrophagocytosis) and neutro-
phils. It is important to note that PRDX6 relocates to the cell membrane during neutrophil activation38, which is 
required for optimal NADPH oxidase activity. The localization of PRDX6 in VSMCs of the AAA wall is probably 
a response to increased oxidative stress39, since PRDX6 expression in VSMCs is known to increase in response 
to H20240. Other oxidative stress markers identified in AAA tissue include the lipid peroxidation marker MDA 
and ceroids, which mark oxidation associated with lipids and RBCs19. We detected colocalization of PRDX6 with 
ceroids and MDA in the AAA thrombus; moreover, an intense PRDX6 signal was detected in cholesterol-rich and 
acellular atherosclerotic plaques in the AAA wall, colocalizing with MDA-positive areas. Cell-associated PRDX6 
thus might participate in redox imbalance in AAA tissue through protective antioxidant functions or deleterious 
neutrophil-dependent NADPH activation; however, in a highly oxidative environment such as AAA, PRDX6 may 
lose its antioxidant activities through oxidative modification by lipid hydroperoxides41. Whether PRDX6 plays a 
protective or deleterious role in AAA tissue deserves further investigation.
Our finding that ex-vivo incubation of HDLs with lysed RBCs increases HDL levels of PRDX6 and catalase 
suggests that part of the PRDX6 observed in AAA thrombus may arise from RBC lysis. However, increased levels 
Figure 7. ELISA analysis of PRDX6 in AAA patient plasma. (a) Plasma concentration of PRDX6 in a cohort 
of control participants (N = 27) and AAA patients (N = 47)(**p < 0.01). (b) Correlation between PRDX6 and 
AAA size (r = 0.4, p < 0.001, age-adjusted).
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of PRDX6, but not catalase, were also observed in HDLs incubated with intact RBCs, suggesting that HDLs may 
interact directly with membrane-bound PRDX6 in RBCs. In any case, PRDX6 translocation to the cell membrane 
is important for reactive oxygen species production through NADPH oxidase 2 complex activation34,38, suggest-
ing that the elevated PRDX6 levels in circulating HDL of AAA patients reflect an increased systemic oxidative 
stress. Our study not only identifies PRDX6 as a HDL constituent, but also shows that PRDX6 concentration 
doubles in the plasma of AAA patients, probably reflecting the systemic response to increased oxidative stress in 
AAA. We also found a positive correlation between PRDX6 and AAA size, a marker of AAA progression and the 
clinical parameter used in the management of AAA patients.
Our analysis suggests that the altered protein profile of HDLs in AAA reflects disease events, including an 
increase in antioxidant proteins probably associated with a systemic response to the redox imbalance in AAA. The 
increased HDL and plasma levels of PRDX6 in AAA patients support the potential of PRDX6 as a new biomarker 
of AAA.
Methods
The authors declare that all methods were performed in accordance with the relevant guidelines and regulations.
Patient selection. The studies were approved by the Research and Ethics Committee of the Fundación 
Jiménez Díaz University Hospital Health Research Institute (IIS-FJD; Madrid, Spain), and patients and control 
participants gave informed consent for their inclusion in the study. Patients with an asymptomatic infrarenal 
AAA (aortic size > 3 cm confirmed by abdominal ultrasound) were recruited during clinical examination or 
before surgical repair at the Vascular Surgery Service at FJD University Hospital. Controls with non-dilated 
infrarenal aortas (aortic size < 3 cm, confirmed by abdominal ultrasound) were recruited through a screening 
program. For proteomic analysis, EDTA plasma samples were obtained from 14 male AAA patients and 7 male 
control participants. For ELISA, a second set of plasma samples (27 controls and 47 AAA patients) were obtained 
from the IIS-FJD biobank. Clinical characteristics of all controls and AAA patients are summarized in Table 1. 
For immunohistochemistry, samples of AAA thrombus tissue (n = 10) and wall tissue (n = 10) were collected 
from male patients (70 ± 6 years old, 70% hypertensive, 30% current smokers, 50% dyslipidemic, 10% diabetic, 
20% heart disease) undergoing open surgical repair due to aortic dilation > 5 cm at the IIS-FJD Vascular Surgery 
Service.
HDL isolation. Lipoproteins were isolated from individual EDTA plasma samples by ultracentrifugation as 
described in Supplementary Information. Moreover, additional HDLs were isolated from healthy volunteers for 
incubation with red blood cells (RBC)(N = 3). Briefly, HDLs were incubated with RBCs (intact or lysed with 
H2O/NaCl) for 4 hours at 37 °C, and HDLs were subsequently re-isolated by ultracentrifugation.
Proteomics. Proteomic analysis was performed on HDL particles isolated from 14 AAA patients and 7 con-
trols (Table 1). HDL samples were in-gel digested overnight at 37 °C with sequencing-grade trypsin (Promega, 
Madison, WI, USA) at an 8:1 protein:trypsin (w/w) ratio in 50 mM ammonium bicarbonate, pH 8.842. The result-
ing peptides were desalted on C18 Oasis cartridges (Waters Corporation, Milford, MA, USA) using 50% ace-
tonitrile (ACN) (v/v) in 0.1% trifluoroacetic acid (v/v) as eluent, and vacuum dried. A total of 7 independent 
isobaric tags were performed for relative and absolute quantitation (iTRAQ) 4-plex experiments. iTRAQ labeling 
was performed essentially according to the manufacturer’s instructions, as previously described in detail42–44 
(Supplementary Information). In each experiment, samples from 2 AAA patients and 1 control participant were 
compared with an internal control, prepared by pooling protein extracts from all subjects of the study. All the 
comparisons included independent biological preparations, making a total of 14 comparisons between AAA sam-
ples and the internal control sample and 7 comparisons between control samples and the internal control sample. 
The use of the internal control allowed comparison of data from different individuals in different experiments.
The tryptic peptide mixtures were subjected to nano-HPLC (Easy nLC 1000 liquid chromatograph, Thermo 
Scientific, San Jose, CA, USA) coupled to a Q Exactive mass spectrometer (Thermo Scientific). Peptides were sus-
pended in 0.1% formic acid, loaded onto a C18 RP nano-precolumn (75 μ m I.D. and 2 cm, Acclaim PepMap100, 
Thermo Scientific), and separated on an analytical C18 nano-column (75 μ m I.D. and 50 cm, Acclaim PepMap100) 
in a continuous gradient increasing from 8% to 30% B over 120 min, followed by a rapid increase from 30% to 
90% B over 2 min at a flow rate of 200 nL/min. The Q Exactive mass spectrometer was operated in data-dependent 
mode with a normal FT-resolution spectrum (70,000 resolution) in the mass range of m/z 390–1500, followed by 
acquisition of data-dependent MS/MS spectra from the 10 most intense parent ions identified in the chromato-
graphic run.
Peptides were identified by searching against a Human Uniprot database supplemented with porcine trypsin 
(120501 entries; release October 2012). The search was conducted with the SEQUEST algorithm (Proteome 
Discoverer 1.4, Thermo Finnigan), allowing two missed cleavages and using 600 ppm precursor mass tolerance 
and 0.03 ppm fragment mass tolerance. Methionine oxidation and cysteine carbamidomethylation were allowed 
as variable modifications. For peptide iTRAQ labeling, lysine and N-terminal modifications of + 144.1020 Da 
were selected as fixed modifications. The same MS/MS spectra collections were searched against inverted data-
bases constructed from the same target databases. SEQUEST results were analyzed by the probability ratio 
method45; false discovery rates (FDR) for peptide identification were calculated using the refined method46. 
The statistical model used to analyze the quantitative data has been described before in detail43 (Supplementary 
Information). The systems biology analysis was performed using the Systems Biology Triangle (SBT)20.
The data set from the analysis of HDL proteome (raw and msf files, protein database fasta file, searching 
parameters xml file, and excel tables with identification and quantification data) is available in the PeptideAtlas 
repository (http://www.peptideatlas.org/PASS/PASS00861), which can be downloaded via ftp.peptideatlas.org.
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Western blot. Equal amounts of HDL (20 μ g) were loaded onto 10% polyacrylamide gels, electrophoresed 
and transferred to nitrocellulose membranes. Blots were blocked with 7% died skimmed milk in 0.05% 
Tris-buffered saline and Tween (TBS-T) for 1 hour and incubated overnight at 4 °C with the following antibodies: 
anti-PRDX6 (ab16947, abcam), anti-HLA-I (LS-B6775, LifeSpan Biosciences, Inc), anti-paraoxonase (PON1) 
(ab24261, abcam), anti-ApoA1 (home-made), or anti-catalase (ab52477, abcam). ApoA1 was detected as a 
loading control. Membranes were washed with TBS-T and incubated with the appropriate secondary antibody 
(1:2500) for 1 hour at room temperature. After 4 washes, the signal was detected with an ECL chemiluminiscence 
kit (GE Healthcare).
Histology and immunohistochemistry. Samples of arterial wall and intra-luminal thrombus obtained 
from AAA patients were embedded in paraffin, and 4 μ m cross-sections were cut. Ceroids were detected by 
direct observation of tissue by fluorescence microscopy (ceroids autofluoresce at 550 nm, producing a red signal). 
Immunohistochemistry was performed with antibodies against the following proteins: PRDX6 (ab16947, abcam), 
the lipid peroxidation marker MDA (ab6463, abcam), the neutrophil marker CD15 (Dako), and alpha smooth 
muscle actin (Dako). Sections were then incubated with the appropriate biotinylated secondary antibody and 
ABComplex, followed by staining with 3,30-diaminobenzidine (DAB), hematoxylin counterstaining, and mount-
ing in DPX medium.
ELISA. The plasma concentration of soluble PRDX6 in AAA and control samples was measured with a com-
mercial ELISA kit (LF-EK0206, AbFrontier).
Statistical analysis. Data are expressed as mean ± SEM. Between-group comparisons were assessed for cat-
egorical variables with the X2 test and for numerical variables by Mann-Whitney non-parametric test (ELISA and 
western blot of controls vs patients) or ANOVA followed by Bonferroni test (western blot of in vitro experiment). 
Multivariate logistic regression analysis included only variables that were statistically significant in the univar-
iate analysis, and was performed to assess predictors of the presence of AAA. Univariate association of PRDX6 
with AAA size was assessed by the Pearson correlation test and then adjusted for age. Ninety-five percent confi-
dence intervals (CI) were calculated for each comparison. Differences were considered statistically significant at 
p < 0.05. Statistical analysis was performed with SPSS 15.0.
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